Proteomics and Dimerix partner to improve the treatment of kidney disease
Australia-based Proteomics International (PI) has developed PromarkerD, a predictive and diagnostic test for diabetic kidney disease that measures a protein…
Tianhe Life Sciences leads $9.5m Series A in Clover Biopharma
Tianhe Life Sciences leads $9.5m Series A in Clover Biopharma Clover is utilising its proprietary Trimer-Tag technology platform to develop…
PathoQuest and Mayo Clinic Enter into an Agreement to Conduct Study of iDTECT™ Blood in Patients with Febrile Neutropenia
PathoQuest, a life sciences leader focused on improving pathogen identification in biological samples, today announced that it will conduct research…
Pegfilgrastim Biosimilar Matches Reference Product
Sandoz’s biosimilar of Neulasta, or pegfilgrastim, matched the reference product in a clinical trial, according to the company. Researchers found…
Discontinuation of Sanofi’s C. difficile Vaccine Program presents an opportunity for Pfizer and Valneva, observes GlobalData
On December 1 2017, Sanofi Pasteur announced its intention to discontinue the Phase III development program for its Clostridium difficile…
British trial results promising for Huntington’s drug
UCL scientists have successfully completed the first human trial of the drug that targets the cause of Huntington’s disease. After…
LaJolla Pharma launches mid-stage study of LJPC-401 in iron overload disorder
LaJolla Pharmaceuticals initiates a Phase 2 clinical trial assessing LJPC-401 (synthetic human hepcidin) in patients with hereditary hemochromatosis, a deficiency of…
Targovax announces that TG02 has passed the initial safety review in the first-in-man clinical trial in colorectal cancer
Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces that…
FDA lifts clinical hold on fitusiran
Sanofi Genzyme, the specialty care global business unit of Sanofi, and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics…